Resource Centers
Regulatory Compliance
Videos
Blinded Diagnostics - Partnerships 12
Paul Savuto, President and CFO, and Steven Karrupan, CEO, from Blinded Diagnostics discuss Point of Care Technology at Partnerships in Clinical Trials 2012. Point of care (or decentralized testing) offers the opportunity for sponsors and Clinical Research Organizations (CROs) to perform clinical trials with testing results available in minutes rather than days. The data is available to be analyzed on site as opposed to having to ship to a central lab, cutting shipping costs. Point of care testing in clinical trials is also an excellent solution for patient enrollment and screening as well as blended studies and adaptive trials. Faster results means better opportunity for trend analysis. Point of care is also available in any location - from the isolation of a patient's home or a remote area to a large city.
Make sure you enter the (*) required information where indicated. HTML code is not allowed.
Steven Cutler, Group President of ICON discusses the launch of ICON's new acquisition of Firecrest at Partnerships in Clinical Trials 2012. Facing the continuing challenge of not only monitoring and…
Steven Cutler, Group President of ICON discusses their exciting new partnership with Roche at Partnerships In Clinical Trials 2012. Medical imaging has always been a strong department within ICON. ICON…
John Blakely, Executive Vice President and Chief Commercial Officer for ERT discusses the new trend in clinical research at Partnerships in Clinical Trials 2012 - the melding of objective and…
Marcelo Piccirillo, Senior Clinical Research Physician for Chiltern, discusses new trends in gastrointestinal clinical development at Partnerships in Clinical Trials 2012. Current hot spots for clinical development in the field…
Paul Savuto, President and CFO, and Steven Karrupan, CEO, from Blinded Diagnostics discuss Point of Care Technology at Partnerships in Clinical Trials 2012. Point of care (or decentralized testing) offers…
American Airlines has globally launched a passive solutions that gives a new alternative to pharmaceutical manufacturers.